Atea ASA engages in the business of supplying information technology infrastructure solutions in the Nordic and Baltic countries. The company is headquartered in Oslo, Oslo and currently employs 8,165 full-time employees. The Company’s subsidiaries are engaged in the provision of Information Technology (IT) infrastructure products and services for businesses and public-sector organizations in Europe. They offer a range of hardware and software products as well as Information Technology (IT) infrastructure support and advice to the companies within the technology sector. Atea ASA’s operations are divided into six segments: Norway, Sweden, Denmark, Finland and The Baltics segments, that reflect the Company’s operation range as well as the Shared Services segment. Atea ASA operates through several subsidiaries, including Atea Holding OY, Atea Global Services SIA, Atea Holding AB and Atea Baltic UAB.
TScan Therapeutics Inc 最大收入来源是 T Cell Receptor-engineered T Cell,在最近的收益报告中收入为 2,816,000。就地区而言, United States 是 TScan Therapeutics Inc 的主要市场,收入为 2,816,000。